Atea Pharmaceuticals Inc (AVIR) Stock Price, Quote & News

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection....

Industry: Biotechnology

Sector: Healthcare

Phone: 857 284 8891

Website: ateapharma.com

Address:

225 Franklin Street, Suite 2100, Boston, United States

StocktwitsEarnings Aug. 12 at 10:14 PM

$AVIR Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.41 up 6.82% YoY

0 · Reply

EarningsInsider Aug. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-8-12-atea-pharmaceuticals-inc-stock/ $AVIR Atea Pharmaceuticals Earnings Transcript

0 · Reply

TooMuchFinesse Aug. 10 at 6:21 PM

$AVIR Seems like some ppl don’t know why they’re here. Others do. $6.50 per share in net cash? Start loading next week

1 · Reply

TooMuchFinesse Aug. 10 at 5:15 PM

$CMPX $CMPS $AVIR $PMVP $VIR PMVP is the diamond in the ruff out of all these. The other 4 are pure money bags. Kind of late if you’re entering CMPS. Trading on momentum really. But the others you can stack and wait for Positive PR

1 · Reply

laaarsas Aug. 8 at 10:55 AM

$AVIR huge breakout! Next target 5.60!

0 · Reply

laaarsas Aug. 8 at 10:54 AM

$AVIR YES. WENT UP BIG. AHAHAH. NOW MARKET REALISE! MARKET SHARE FOR HEP C IS A REAL POSSIBILITY!!

0 · Reply

ExploringTrades Aug. 4 at 7:56 PM

Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $AVIR atch it

1 · Reply

laaarsas Aug. 4 at 3:18 PM

$AVIR Where is is insider buyer???

0 · Reply

ichigo_ichie Aug. 4 at 2:13 PM

$AVIR One of these things is not like the others. 1/ The DOG ate my homework 2/ WE will keep your resume on file. 3/ ATEA Pharmaceuticals meets both Primary and Secondary Endpoints in Phase 3 Hepatitis C North American Trial.

1 · Reply

laaarsas Aug. 4 at 12:49 PM

$AVIR Why NOT UP!? WHERE IS NEW TARGET PRICE??

0 · Reply

Atea Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 10 hours ago

Atea Pharmaceuticals Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 10 hours ago

Atea Pharmaceuticals Slides: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 10 hours ago

Atea Pharmaceuticals Quarterly report: Q2 2026

Aug 12, 2026, 4:05 PM EDT - 11 hours ago

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 5, 2026, 7:00 AM EDT - 7 days ago

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

2026-07-28T11:21:17.000Z - 15 days ago

Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

Jul 28, 2026, 7:00 AM EDT - 15 days ago

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

2026-07-14T11:05:25.000Z - 4 weeks ago

Atea Pharmaceuticals initiates AT-587 clinical trial

Jul 14, 2026, 7:00 AM EDT - 4 weeks ago

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

2026-06-25T11:10:59.000Z - 6 weeks ago

Atea Pharmaceuticals completes patient enrollment in C-FORWARD trial

Jun 25, 2026, 7:00 AM EDT - 6 weeks ago

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Jun 18, 2026, 9:00 AM EDT - 7 weeks ago

Atea Pharmaceuticals Transcript: AGM 2026

May 27, 2026, 7:00 AM EDT - 2 months ago

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

May 12, 2026, 4:30 PM EDT - 3 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Atea Pharmaceuticals Slides: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Atea Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 3 months ago

Atea Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 4:05 PM EDT - 3 months ago

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 7:00 AM EDT - 3 months ago

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Atea Pharmaceuticals Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Atea Pharmaceuticals Proxy statement: Proxy filing

2026-03-09T12:05:33.000Z - 5 months ago

Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI

Mar 5, 2026, 4:30 PM EST - 5 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 4:30 PM EST - 5 months ago

Atea Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 4:30 PM EST - 5 months ago

Atea Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 4:30 PM EST - 5 months ago

Atea Pharmaceuticals Slides: Q4 2025

Mar 5, 2026, 4:05 PM EST - 5 months ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 5 months ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

2026-02-24T12:40:00.000Z - 6 months ago

Atea Pharmaceuticals presents preclinical results of AT-587

Feb 24, 2026, 7:00 AM EST - 6 months ago

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Jan 15, 2026, 10:30 AM EST - 7 months ago

Atea Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 10:30 AM EST - 7 months ago

Atea Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-08T12:17:39.000Z - 7 months ago

Atea Pharmaceuticals to highlight strategic priorities for FY26

Jan 8, 2026, 7:00 AM EST - 7 months ago

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 7 months ago

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-22T12:06:16.000Z - 8 months ago

Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial

Dec 22, 2025, 7:00 AM EST - 8 months ago

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Dec 3, 2025, 10:00 AM EST - 9 months ago

Atea Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 19, 2025, 7:00 AM EST - 9 months ago

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 10:00 AM EST - 9 months ago

Atea Pharmaceuticals Transcript: Status Update

Nov 12, 2025, 4:30 PM EST - 9 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Atea Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Atea Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Atea Pharmaceuticals Slides: Q3 2025

Nov 12, 2025, 4:05 PM EST - 9 months ago

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-07T13:10:51.000Z - 9 months ago

Atea Pharmaceuticals announces presentation of data on BEM, RZR

Nov 7, 2025, 8:00 AM EST - 9 months ago

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Nov 5, 2025, 7:00 AM EST - 10 months ago

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

Oct 22, 2025, 7:00 AM EDT - 10 months ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

2025-10-07T12:20:17.000Z - 11 months ago

Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Sep 9, 2025, 1:05 PM EDT - 1 year ago

Atea Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Atea Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Atea Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Atea Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

2025-06-24T11:10:21.000Z - 1 year ago

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

May 14, 2025, 10:00 AM EDT - 1 year ago

Atea Pharmaceuticals Transcript: Status Update

May 12, 2025, 4:11 PM EDT - 1 year ago

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:00 PM EDT - 1 year ago

Atea Pharmaceuticals Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Atea Pharmaceuticals Earnings release: Q1 2025

2025-05-07T11:41:58.000Z - 1 year ago

Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir

May 7, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

2025-05-01T11:36:00.000Z - 1 year ago

Atea Pharmaceuticals to host hepatitis C virus KOL panel

May 1, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing

2025-04-23T11:10:53.000Z - 1 year ago

Atea Pharmaceuticals announces results from phase 2 study of bemnifosbuvir

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

2025-04-17T11:14:42.000Z - 1 year ago

Atea Pharmaceuticals board authorizes $25M share repurchase program

2025-04-17T11:14:02.000Z - 1 year ago

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’

2025-04-17T11:05:10.000Z - 1 year ago

Atea Pharmaceuticals appoints Howard Berman to board of directors

COYA

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

2025-04-11T13:10:23.000Z - 1 year ago

Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley

2025-04-09T11:11:45.000Z - 1 year ago

Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing

Mar 31, 2025, 7:04 PM EDT - 1 year ago

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination

2025-03-26T18:10:10.000Z - 1 year ago

Atea Pharmaceuticals cuts 25% of workforce, exploring partnerships

Mar 26, 2025, 1:58 PM EDT - 1 year ago

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

2025-03-26T12:17:05.000Z - 1 year ago

Radoff-JEC Group nominates candidates to Atea Pharmaceuticals board

Mar 26, 2025, 8:00 AM EDT - 1 year ago

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Atea Pharmaceuticals Proxy statement: Proxy Filing

Mar 21, 2025, 5:54 PM EDT - 1 year ago

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Annual report: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings release: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Slides: Q4 2024

Mar 6, 2025, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Jan 15, 2025, 8:15 PM EST - 1 year ago

Atea Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 8:15 PM EST - 1 year ago

Atea Pharmaceuticals Slides: FY 2025

Jan 8, 2025, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 5:05 PM EST - 1 year ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

Dec 16, 2024, 5:00 AM EST - 1 year ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

Dec 4, 2024, 9:35 AM EST - 1 year ago

Atea Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 4, 2024, 9:35 AM EST - 1 year ago

Atea Pharmaceuticals Slides: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 4, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

Nov 15, 2024, 11:00 AM EST - 1 year ago

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 4:05 PM EST - 1 year ago

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 7:00 AM EST - 1 year ago

Atea Pharmaceuticals Registration statement: Registration Filing

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Sep 13, 2024, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Aug 28, 2024, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Earnings release: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Slides: Q2 2024

Jul 31, 2024, 7:00 AM EDT - 2 years ago

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

StocktwitsEarnings Aug. 12 at 10:14 PM

$AVIR Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.41 up 6.82% YoY

0 · Reply

EarningsInsider Aug. 12 at 9:32 PM

https://www.marketbeat.com/earnings/reports/2026-8-12-atea-pharmaceuticals-inc-stock/ $AVIR Atea Pharmaceuticals Earnings Transcript

0 · Reply

TooMuchFinesse Aug. 10 at 6:21 PM

$AVIR Seems like some ppl don’t know why they’re here. Others do. $6.50 per share in net cash? Start loading next week

1 · Reply

TooMuchFinesse Aug. 10 at 5:15 PM

1 · Reply

laaarsas Aug. 8 at 10:55 AM

$AVIR huge breakout! Next target 5.60!

0 · Reply

laaarsas Aug. 8 at 10:54 AM

$AVIR YES. WENT UP BIG. AHAHAH. NOW MARKET REALISE! MARKET SHARE FOR HEP C IS A REAL POSSIBILITY!!

0 · Reply

ExploringTrades Aug. 4 at 7:56 PM

1 · Reply

laaarsas Aug. 4 at 3:18 PM

$AVIR Where is is insider buyer???

0 · Reply

ichigo_ichie Aug. 4 at 2:13 PM

1 · Reply

laaarsas Aug. 4 at 12:49 PM

$AVIR Why NOT UP!? WHERE IS NEW TARGET PRICE??

0 · Reply

laaarsas Aug. 3 at 2:24 PM

$AVIR GO UP NOT DOWN

0 · Reply

laaarsas Jul. 30 at 4:33 PM

$AVIR Go more big!! Break 5 this week!!

0 · Reply

ichigo_ichie Jul. 29 at 6:18 PM

$AVIR as far as Avir’s current pps since the fantastic Phase 3 positive public press release could we explore if the equity markets are as efficient as scholars would have us theorize and if the stated pps is a result of irrationality?

0 · Reply

GunFinger Jul. 29 at 5:31 PM

$AVIR Keep an eye out for this one 👀 $256M in cash (as of Q1 2026), funding secured until the end of 2027, no recent dilution, and a full $200M ATM still available. They’re funded to complete C-FORWARD, prepare regulatory filings, advance the HEV program, and move toward commercialization without needing to raise capital anytime soon. Strong balance sheet + clear path forward.

1 · Reply

Following_the_trend Jul. 29 at 1:41 PM

$AVIR Looking better today so far

0 · Reply

laaarsas Jul. 29 at 10:21 AM

$AVIR When will this be recognised?

0 · Reply

Cutlass Jul. 28 at 7:59 PM

$AVIR Good Bounce off 3.82 👀

0 · Reply

laaarsas Jul. 28 at 7:56 PM

$AVIR Omg I even should have bought the dip ahahahah!

0 · Reply

laaarsas Jul. 28 at 7:29 PM

$AVIR We close week above 5! No losses has to be made!!

0 · Reply

laaarsas Jul. 28 at 7:28 PM

$AVIR Ahaha!!! Big regain!! AhaHa°!

0 · Reply

laaarsas Jul. 28 at 6:35 PM

$AVIR Ticking up from the slurp market realizing it is retarded. New higher target prices will come tomorrow.

0 · Reply

prismmarketview Jul. 28 at 5:37 PM

$AVIR Atea’s C‑BEYOND Phase 3 study in hep C was successful, backing its bemnifosbuvir/ruzasvir oral regimen as a next‑gen, short‑duration treatment. Watching next data from C‑FORWARD. #AVIR #HepatitisC #BiotechStocks #ClinicalData https://prismmarketview.com/ateas-hepatitis-c-breakthrough-new-short-course-pill-regimen-clears-phase-3-c-beyond-trial/

0 · Reply

Market Cap	404.14M
Revenue (ttm)	0.00
Net Income (ttm)	-158.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	292,100
Avg Vol	345,118
Day's Range	N/A - N/A
Shares Out	80.03M
Stochastic %K	68%
Beta	0.30
Analysts	Sell
Price Target	$8.00